Sponsorship Alliance News

News from Our Sponsorship Alliance Partners

June 2024

AstraZeneca Pharmaceuticals

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not reach statistical significance.

TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population.

Results support applications currently under review by regulatory authorities globally including in the US and EU.

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings

May 2024


Elekta and GE HealthCare’s MIM Software enter significant collaboration to deliver leading cancer treatment planning solutions

Elekta and MIM Software Inc., a leading provider of medical imaging management and artificial intelligence solutions, recently acquired by GE HealthCare, announce their collaboration to combine best-of-breed solutions for advanced treatment planning in the delivery of radiation therapy. The strategic collaboration aims to accelerate innovation in software solutions that will benefit clinics with improved workflows, higher throughput, and enhanced user experience, while for patients, provide greater precision in their treatment and less time spent at the hospital.  


AEx Rewind: SBRT for Central and Ultra‐Central Early‐Stage Inoperable Non‐Small Cell Lung Cancer

 AEx Rewind Webinar: SBRT for Central and Ultra-Central Early-Stage Inoperable Non-Small Cell Lung Cancer is now available on demand. This informative session explores treatment options for patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC). Don't miss this opportunity to gain valuable insights into managing CLC/UCLC patients through SBRT.

ZAP Surgical

ZAP-X in the news! ZAP-X cleared to treat in China.

Future Brain Therapy: Cutting-edge radiotherapy device offers hope for Chinese brain tumor patients. recently received official treatment approval in China.  Watch the news segment here.

World-class SRS in a simple modular building!

A cost-effective, rapid deployment of state-of-the-art radiosurgery made possible with the vault-free, cobalt-free ZAP-X. Congratulations to the teams at Miami Cancer Institute and Baptist Health for initiating patient treatments in this entirely novel and pioneering setting. Learn more how ZAP-X creates elite neuro-oncology programs anywhere, everywhere. Visit https://zapsurgical.com/

April 2024

ZAP Surgical

ZAP Surgical Announces Additional Installation of Its State-of-the-Art ZAP-X Brain Tumor Treatment System in New York State

Neurosciences and Spine Group in Vestal to Bring Access to State-of-the-Art Radiosurgery to Southern New York and Surrounding Communities

Just published: ZAP-X Prospective Patient Study

100 patients with wide ranging indications including multiple mets, vestibular schwannoma, meningioma, AVM, etc. Request a copy: info@zapsurgical.com.

Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor Treatment in South Asia

Milestone Reinforces Mutual Commitment to Advancing Healthcare Through Greater Access to State-of-the-Art Medical Technologies.

Redefining Advanced SRS - Without the Vault!

See stunning video footage of the new ZAP-X program at Hacettepe University.

The Ohio State University

A Novel Radiosurgical Treatment for Spasticity: Preliminary Results from a Sham-Controlled Prospective Trial

Frameless LINAC radiosurgery directed to the sensory region of selected nerve roots has been recently described as a novel treatment option to relieve severe spasticity . A prospective Sham-Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery versus Standard of Care for Spasticity Associated with Stroke, Spinal Cord Injury and Cerebral Palsy is currently underway to provide a solid assessment about the efficacy and safety of this novel treatment.


RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning

RefleXion and Limbus AI, a provider of software solutions for cancer radiation therapy, announced a technology integration agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system. This integration will reduce the most significant bottleneck in the patient treatment planning process, which involves delineating the tumor target from surrounding critical organs and other healthy tissue.


New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

New data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois supports the use of the CyberKnife® System in treating high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of the disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams. "Health-Related Quality of Life Following Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer." [https://www.rssevents.org/fsPopup.asp?PosterID=658464&mode=posterInfo] "Acute Toxicity Following PSMA-Directed Focal Salvage Robotic SBRT for Local Recurrences Following Prior Robotic Prostate SBRT." [https://www.rssevents.org/fsPopup.asp?PosterID=658489&mode=posterInfo]

NYU Langone

NYU-PCC Long Island Radiation Oncology at the International Radiosurgery Society Meeting

NYU-PCC Long Island Radiation Oncology at the International Radiosurgery Society Meeting

MD Anderson Cancer Center

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

Stereotactic ablative radiotherapy (SABR) has shown benefit in early-stage non–small cell lung cancer (NSCLC) and has also shown clinical benefit in combination with immunotherapy, making it a viable treatment option to consider, according to a presentation given by Joe Y. Chang, MD, PhD, during The Radiation Oncology Summit: ACRO 2024. Chang explained that immunotherapy plus SABR could be evaluated as a curative approach.

March 2024

ZAP Surgical

ZAP-X Gyroscopic Radiosurgery Platform Set to Revolutionize Neurosurgery at N. Copernicus Hospital in Gdansk

Installation Marks the Second ZAP-X System in Poland for State-of-the-Art, Non-Invasive Treatment of Brain Tumors


Geisinger now equipped for GammaTile Therapy

As of January 2024, Geisinger is now equipped to conduct GammaTile Therapy procedures. “GammaTile Therapy uses radioactive cesium seeds embedded in collagen sheets to deliver safe and effective radiotherapy for patients with a wide variety of brain tumors,” said Charles T. Lee, MD, radiation oncology, Geisinger. GammaTile Therapy is best for patients with recurring tumors that have previously been treated with radiation as it allows the safe delivery of higher doses than would be allowed by traditional approaches. “The GammaTile is placed during the time of surgery and reduces the number of trips the patient needs to make to their local radiation treatment facility,” added Dr. Lee. Geisinger will continue to provide updates via the Radiosurgery Society.

NYU Langone

Perlmutter Cancer Center at NYU - Long Island Begins Enrollment in Two-Treatment CyberKnife Study

Perlmutter Cancer Center at NYU - Long Island Radiation Oncology announced that it has begun enrolling and treating eligible CyberKnife patients with prostate cancer on an IRB-approved protocol that will last just two treatments rather than the usual five. They will also be integrating genomics into this particular study to intensify or deintensify the radiation based on a patient's personalized genomic pattern. Expect to hear more about this study at the free screening and education day that is being scheduled to take place in NYU's Mineola location in the spring.

MD Anderson Cancer Center

MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide

The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre. Working together, MD Anderson and the IAEA aim to enhance radiation oncology, radiation physics, radiology, nuclear medicine and nutrition globally. MD Anderson operates the most comprehensive radiation oncology facility in the world and will be the first IAEA Collaborating Centre in the United States focused on health care.


First City of Hope Patient Treated Using SCINTIX Therapy

City of Hope has treated their first patient using SCINTIX biology-guided radiotherapy. Learn more about this exciting milestone in their recent blog.

BIOGUIDE-X First-in-Human Study Published in Red Journal

The BIOGUIDE-X study is the newest addition to the growing body of scientific evidence supporting SCINTIX biology-guided radiotherapy. Click below to read more about this article, published in the Red Journal, which covers the clinical investigation and novel trial design that led to FDA clearance for SCINTIX therapy in primary and metastatic lung and bone tumors.

Vision RT, Inc.

Full Agenda Announced: SGRT Community Meeting

As the sponsor of the SGRT Community, Vision RT is pleased to announce the full agenda for this year's annual meeting. What better way to learn how SGRT can help improve the safety, effectiveness and efficiency of your workflows than to reserve your place in the sun at this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.

Varian Medical Systems

Varian Receives FDA 510(k) Clearance for TrueBeam and Edge Radiotherapy Systems Featuring HyperSight Imaging Solution

Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution. By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators. HyperSight empowers clinicians to accurately tailor treatments to each individual patient with the goal of improving patient outcomes.

February 2024


CMS Assigns Accretive Reimbursement for RefleXion’s Breakthrough SCINTIX Therapy

RefleXion announced that the Centers for Medicare and Medicaid Services (CMS) has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology (NT) Ambulatory Payment Classification (APC) pathway. This pathway is reserved for novel procedures that are not represented in the existing reimbursement claims data used to describe new procedures and their associated resources.